Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | The role of isatuximab in the management of MM

Mohamad Mohty • 9 Jun 2020
EHA 2020
Multiple Myeloma Antibodies Carfilzomib Dexamethasone Isatuximab
CANDOR ICARIA-MM IKEMA

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the role of isatuximab in the management of multiple myeloma (MM). Particularly, Prof. Mohty mentions the IKEMA study (NCT03275285), investigating isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory MM. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Mohamad Mohty

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:24
Comparing alloSCT outcomes in secondary and de-novo acute lymphoblastic leukemia
Mohamad Mohty • 15 Feb 2024
4:17
The evolving role of autoSCT in the age of CAR-T for multiple myeloma: current & future perspectives
Mohamad Mohty • 15 Feb 2024

Related Videos

4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals